CAR T-cell (Chimeric Antigen Receptor) therapy is helping usher in the age of
personalized medicine by programming the patients’ own immune cells to target
previously undetected cancerous cells. Used to treat certain blood cancers,
CAR-T cell therapy boasts outstanding treatment efficacy and high specificity.
Further research is ongoing to expand the scope of treatment to solid tumors as well.
NEST platform- Targeting novel sites of disease proteins to reveal new antibody effects.
NEST (Novel Epitope Screening Technology) platform allows for development of
antibodies targeting unique sites of disease proteins. By targeting previously
unknown sites, these new antibodies exhibit completely different therapeutic
effects compared to conventional antibody treatments.
Allows for agile development of bispecific antibodies that can simultaneously target two disease proteins.
AffiMab is a platform that combines the advantages of monoclonal antibodies and
Affibody molecules. It allows for agile development of bispecific antibodies that
can maximize therapeutic effects compared to conventional antibody treatments
in refractory diseases.
With diverse technologies ranging from NEST to CAR-T platforms, AbClon is focused
on the development of innovative antibody therapeutics. AbClon’s mission is to
push the boundaries of science to develop therapeutics that demonstrate
better efficacy and target once incurable diseases.
AbClon creates new therapeutic opportunities for breakthroughs in human health.
YOUR HOPE WE KEEP
AbClon Inc. #1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
T. +82-2-2109-1294 F. +82-2-2109-1296 E. firstname.lastname@example.org